Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Moderate-to-Severe ARDS: A Phase III Clinical Trial

Status: Recruiting
Location: See all (38) locations...
Intervention Type: Biological, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Men and women aged 18-75 years of age

• Presence of the following criteria for moderate to severe ARDS as defined by the Berlin Criteria within 24 hours of the first infustion:

‣ Onset within 7 days of known clinical insult or requiring increasing respiratory rate, increasing oxygen flows, or increased work of breathing, and

⁃ Bilateral lung opacities not fully explained by pleural effusions, atelectasis, or nodules, and

⁃ PaO2/FiO2 (P/F ratio) ≤ 200 mm Hg, and

⁃ Invasive or noninvasive ventilation with a minimum PEEP 5 cm H2O or minimum of continuous positive airway pressure (CPAP) 5 cm H2O, or High Flow Nasal Oxygen at ≥ 30 L/min, and

⁃ Respiratory failure not fully explained by cardiac failure or fluid overload.

Locations
United States
Alabama
Direct Biologics Investigational Site
RECRUITING
Birmingham
Arkansas
Direct Biologics Investigational Site
RECRUITING
Little Rock
Arizona
Direct Biologics Investigational Site
RECRUITING
Chandler
Direct Biologics Investigational Site
RECRUITING
Phoenix
California
Direct Biologics Investigational Site
RECRUITING
Davis
Direct Biologics Investigational Site
RECRUITING
Fullerton
Direct Biologics Investigational Site
RECRUITING
Irvine
Direct Biologics Investigational Site
RECRUITING
Orange
Direct Biologics Investigational Site
RECRUITING
Sacramento
Direct Biologics Investigational Site
RECRUITING
San Francisco
Washington, D.c.
Direct Biologics Investigational Site
RECRUITING
Washington D.c.
Florida
Direct Biologics Investigational Site
RECRUITING
Jacksonville
Iowa
Direct Biologics Investigational Site
RECRUITING
Iowa City
Idaho
Direct Biologics Investigational Site
RECRUITING
Boise
Kansas
Direct Biologics Investigational Site
RECRUITING
Wichita
Massachusetts
Direct Biologics Investigational Site
RECRUITING
Boston
Direct Biologics Investigational Site
RECRUITING
Burlington
Direct Biologics Investigational Site
RECRUITING
Springfield
Maryland
Direct Biologics Investigational Site
RECRUITING
Silver Spring
Michigan
Direct Biologics Investigational Site
RECRUITING
Ann Arbor
Direct Biologics Investigational Site
RECRUITING
Detroit
Mississippi
Direct Biologics Investigational Site
RECRUITING
Jackson
North Carolina
Direct Biologics Investigational Site
RECRUITING
Durham
Direct Biologics Investigational Site
RECRUITING
Winston-salem
New York
Direct Biologics Investigational Site
RECRUITING
Flushing
Direct Biologics Investigational Site
RECRUITING
Queens
Direct Biologics Investigational Site
RECRUITING
The Bronx
Ohio
Direct Biologics Investigational Site
RECRUITING
Cincinnati
Direct Biologics Investigational Site
RECRUITING
Cleveland
Oregon
Direct Biologics Investigational Site
RECRUITING
Portland
South Carolina
Direct Biologics Investigational Site
RECRUITING
Charleston
Tennessee
Direct Biologics Investigational Site
RECRUITING
Knoxville
Direct Biologics Investigational Site
RECRUITING
Nashville
Texas
Direct Biologics Investigational Site
RECRUITING
Dallas
Direct Biologics Investigational Site
RECRUITING
Fort Worth
Direct Biologics Investigational Site
RECRUITING
Houston
Utah
Direct Biologics Investigational Site
RECRUITING
Murray
Direct Biologics Investigational Site
RECRUITING
Salt Lake City
Contact Information
Primary
Bill Arana
clinicalaffairs@directbiologics.com
1-800-791-1021
Time Frame
Start Date: 2022-07-01
Estimated Completion Date: 2025-08-31
Participants
Target number of participants: 970
Treatments
Placebo_comparator: Placebo
Normal saline 100 mL
Experimental: Experimental Dose
Normal saline 85 mL and ExoFlo 15 mL
Sponsors
Leads: Direct Biologics, LLC

This content was sourced from clinicaltrials.gov